TapImmune Inc (TPIV)

3.00
0.05 1.63
NASDAQ : Health Care
Prev Close 2.95
Open 3.00
Day Low/High 3.00 / 3.01
52 Wk Low/High 2.68 / 7.15
Volume 2.56K
Avg Volume 43.50K
Exchange NASDAQ
Shares Outstanding 10.16M
Market Cap 27.94M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TapImmune Provides First Quarter 2017 Corporate And Clinical Update

Conference Call and Live Audio Webcast Scheduled for Today at 4:30 pm ET

TapImmune To Provide First Quarter 2017 Business Update Conference Call And Webcast

Company to Provide Corporate and Clinical Overview on Wednesday, May 31, 2017, 4:30pm ET

Richard Kenney, MD, FACP, Joins TapImmune To Lead The Clinical Development Program

Seasoned Vaccinologist with extensive experience in Immunotherapy Clinical Trials

TapImmune Provides Year End 2016 Corporate And Clinical Update

Conference Call and Live Audio Webcast Scheduled for Today at 4:30 pm ET

TapImmune Announces Fully Funded Phase 2 Clinical Study Of HER2-Targeted Vaccine In Early Breast Cancer

Collaborators at Mayo Clinic Secure New $3.7 Million Grant from U.S. Department of Defense

TapImmune To Host Inaugural Quarterly Business Update Conference Call And Webcast

Company to Provide Corporate and Clinical Overview on Tuesday, March 14, 2017, 4:30pm ET

TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review

Independent Review Board Confirms Interim Safety Profile of TPIV 200

TapImmune Expands Intellectual Property On PolyStart™ Platform For Use In Next-Generation T-Cell Vaccines

Receives Notice of Allowance for New Patent Covering Expression of Specific Antigens

TapImmune Provides Update On PolyStart™ Vaccine Platform Applicable To Cancer And Infectious Disease

TapImmune Provides Update On PolyStart™ Vaccine Platform Applicable To Cancer And Infectious Disease

TapImmune, Inc. (OTCBB:TPIV), provides an update on the status of its PolyStart TM vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola...

TapImmune CEO Provides Update On Corporate Activity And Progression Of Clinical Programs

TapImmune CEO Provides Update On Corporate Activity And Progression Of Clinical Programs

TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease.

TapImmune Releases Positive Interim Data On Phase I Clinical Trial Of Folate Receptor Alpha Antigens In Ovarian And Breast Cancer

TapImmune Releases Positive Interim Data On Phase I Clinical Trial Of Folate Receptor Alpha Antigens In Ovarian And Breast Cancer

TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell ...

TapImmune, Inc. Announces $2 Million Registered Direct Offering

TapImmune, Inc. Announces $2 Million Registered Direct Offering

TapImmune, Inc. (the “Company”), (OTCQB:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a ...

TapImmune's New Clinical Trial In Advanced Stage Ovarian Cancer Expands The Use Of Folate Receptor Alpha Peptide Antigens

TapImmune's New Clinical Trial In Advanced Stage Ovarian Cancer Expands The Use Of Folate Receptor Alpha Peptide Antigens

TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial...

TapImmune Appoints Leading Immunotherapy Researcher To Chair Scientific Advisory Board

TapImmune Appoints Leading Immunotherapy Researcher To Chair Scientific Advisory Board

TapImmune Inc. (OTCQB:TPIV) is pleased to announce that Dr.

TapImmune Inc. Is Pleased To Provide An Update On Corporate Events And Milestones For 2014

TapImmune Inc. Is Pleased To Provide An Update On Corporate Events And Milestones For 2014

TapImmune Inc. (OTCQB:TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to update ...

TapImmune Closes $1.16 Million Funding

Company Retires Notes and 11.2 Million Warrants

TapImmune Provides Corporate Update

Company Highlights Major Milestones and Developments